• Breast cancer overdiagnosis in women over 70 very common

    Early detection examinations become less useful with age. They often detect abnormalities that would not have developed any clinical relevance.

  • Medical Case: No Lyme disease... or is it?

    A patient noticed a tick in her calf area, which she removed herself. Despite itchy redness, a tick bite was ruled out by a doctor. Could you guess a diagnosis?

  • Vaccinations: current trends and future perspectives

    A review of global childhood immunisation shows that rates increased in 2022 over 2020, but have not yet reached pre-pandemic levels in many countries.

  • Artificial Intelligence: a tool in cancer diagnostics?

    Diagnosis is extensive and complex. In developing countries a detailed evaluation is often out of reach, but an algorithm can detect cancers using AI.

  • Paediatric cancers: genetics and late mortality

    Paediatric cancer patients carrying certain gene variants seem to have higher risks of developing subsequent malignancies and malignancy-related mortality.

  • Medical Drones: Transporting AEDs in rural areas

    A new study suggests that drone-delivery of AEDs to cardiac arrest scenes could reduce unequal emergency response times between urban and rural areas.

  • Medical Case: A student with depressive episodes, gait disorder and double vision

    The symptoms cause the teenager to head into the Emergency Department. Her mother also reports depressive moods. What would you diagnose?

  • Space travel risks: How does the immune system react to zero gravity?

    More than in any previous year, 2023 has seen a rising number of "space tourists". Besides the effects of zero gravitiy, does space impact our immune system?

  • 5 abstracts awarded at UEG WEEK 2023

    The annual international congress took place as a hybrid event in Copenhaguen and online during 14-16 October with over 11,000 participants.

  • Novel drugs for allergy treatment

    Various chronic allergic diseases still need treatment options. Novel agents are under investigation or were approved, diversifying options and increasing efficacy.

  • The topical armamentarium for AD is growing

    With many studies on novel compounds underway, more options for topical treatments of atopic dermatitis (AD) will soon be within reach.

  • Onychomycosis: where do we stand?

    Oral onychomycosis treatment is still the gold standard, but topical armamentarium use is rising, although use of many novel oral and topical agents is off-label.

  • Remibrutinib reduces itch, sleep, and activity impairment in patients with CSU

    In 6 dosage types of remibrutinib, chronic spontaneous urticaria patients benefitted in symptoms such as itch, sleep, and activity, already after 2 weeks.

  • Generalised pustular psoriasis: IL-36 inhibits new flares up to week 48

    IL-36 receptor antibody spesolimab improved erythema, pustulation, and scaling/crusting of skin lesions in generalised pustular psoriasis (GPP).

  • Innovative wound gel significantly reduces daily dressing changes in epidermolysis bullosa

    A post-hoc analysis of the EASE trial revealed that birch extract gel significantly lowered changes, and alleviated the burden of this disease.

  • Differential effect of biologics for psoriasis on the risk of developing arthritis

    A study including 7,144 patients revealed that therapy with IL-23 blockers was associated with lower risk of inflammatory or psoriasis arthritis.

  • Dr Pedro Mendes Bastos on AD differences between children and adults

    Dr Mendes Bastos addressed the heterogeneity of atopic dermatitis patients, causes, and therapy options, and the ongoing research to address them.

  • Promising results in AD treatment with an OX40 ligand inhibitor

    Clinically meaningful improvements in Eczema Area and Severity Index (EASI) were observed with amlitelimab treatment for atopic dermatitis.

  • Skin tape stripping: Can it pave the way for early diagnosis in HS?

    Skin tape stripping is an effective, non-invasive way to detect biomarkers associated with early disease in hidradenitis suppurativa.

  • Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair

    Excluding severe AA, 83–93% of participants in the ALLEGRO-LT trial reached an 80% re-growth of scalp hair or more after 15 months of treatment.

  • 10 |
  • 11 |
  • 12 |
  • 13 |
  • 14 |
  • 15 |
  • 16 |
  • 17 |
  • 18 |
  • 19 |
  • 20 |